Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom

被引:68
作者
Cane, PA [1 ]
de Ruiter, A
Rice, P
Wiselka, M
Fox, R
Pillay, D
机构
[1] Univ Birmingham, Sch Med, Antiviral Susceptibil Reference Unit, Div Immun & Infect,PHLS, Birmingham B15 2TT, W Midlands, England
[2] Leicester Royal Infirm, Dept Infect Dis, Leicester, Leics, England
[3] Guys & St Thomas NHS Trust, Dept Genitourinary Med, London, England
[4] St George Hosp, Dept Virol, London, England
[5] Gartnavel Hosp, Dept Infect Dis, Glasgow, Lanark, Scotland
关键词
D O I
10.1128/JCM.39.7.2652-2654.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This work reports the variability of human immunodeficiency virus type 1 (HIV-1) protease from treated and untreated patients infected with HIV-1 subtype C in the United Kingdom. The most common primary mutation observed in treated patients was L90M. D30N, M46I, V82A/F, and I84V were seen rarely. M36I and I93L mutations were observed in nearly all samples from both treated and untreated patients and so cannot be considered as resistance-associated mutations in this subtype.
引用
收藏
页码:2652 / 2654
页数:3
相关论文
共 16 条
[1]   AT LEAST 5 HIV-1 SEQUENCE SUBTYPES (SUBTYPE-A, SUBTYPE-B, SUBTYPE-C, SUBTYPE-D, SUBTYPE-A/E) OCCUR IN ENGLAND [J].
ARNOLD, C ;
BARLOW, KL ;
PARRY, JV ;
CLEWLEY, JP .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (03) :427-429
[2]   Recombinant strains of HIV type 1 in the United Kingdom [J].
Barlow, KL ;
Tatt, ID ;
Cane, PA ;
Pillay, D ;
Clewley, JP .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (05) :467-474
[3]  
Böni J, 1999, J ACQ IMMUN DEF SYND, V22, P174
[4]   Antiretroviral drug resistance testing in adult HIV-1 infection -: Recommendations of an International AIDS Society-USA panel [J].
Hirsch, MS ;
Brun-Vézinet, F ;
D'Aquila, RT ;
Hammer, SM ;
Johnson, VA ;
Kuritzkes, DR ;
Loveday, C ;
Mellors, JW ;
Clotet, B ;
Conway, B ;
Demeter, LM ;
Vella, S ;
Jacobsen, DM ;
Richman, DD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (18) :2417-2426
[5]   The emerging genetic diversity of HIV - The importance of global surveillance for diagnostics, research, and prevention [J].
Hu, DJ ;
Dondero, TJ ;
Rayfield, MA ;
George, JR ;
Schochetman, G ;
Jaffe, HW ;
Luo, CC ;
Kalish, ML ;
Weniger, BG ;
Pau, CP ;
Schable, CA ;
Curran, JW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (03) :210-216
[6]   Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays [J].
Kozal, MJ ;
Shah, N ;
Shen, NP ;
Yang, R ;
Fucini, R ;
Merigan, TC ;
Richman, DD ;
Morris, D ;
Hubbell, ER ;
Chee, M ;
Gingeras, TR .
NATURE MEDICINE, 1996, 2 (07) :753-759
[7]   Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolate from patients treated with the protease inhibitor nelfinavir [J].
Patick, AK ;
Duran, M ;
Cao, Y ;
Shugarts, D ;
Keller, MR ;
Mazabel, E ;
Knowles, M ;
Chapman, S ;
Kuritzkes, DR ;
Markowitz, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2637-2644
[8]   Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide [J].
Pieniazek, D ;
Rayfield, M ;
Hu, DJ ;
Nkengasong, J ;
Wiktor, SZ ;
Downing, R ;
Biryahwaho, B ;
Mastro, T ;
Tanuri, A ;
Soriano, V ;
Lal, R ;
Dondero, T .
AIDS, 2000, 14 (11) :1489-1495
[9]   Detection of drug resistance associated mutations in HIV primary infection within the UK [J].
Pillay, D ;
Cane, PA ;
Shirley, J ;
Porter, K .
AIDS, 2000, 14 (07) :906-908
[10]   Correlation of response to treatment and HIV genotypic changes during Phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy [J].
Race, E ;
Gilbert, SM ;
Sheldon, JG ;
Rose, JSL ;
Moffatt, AR ;
Sitbon, G ;
Dissanayeke, SR ;
Cammack, N ;
Duncan, IB .
AIDS, 1998, 12 (12) :1465-1474